Oxford, UK and Seattle, WA, USA – 27 September 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, has signed a master services agreement with Immune Design Corp. (Immune Design), a privately held biotechnology company based in Seattle, Washington (USA), which is developing a therapeutic vaccine utilising a lentiviral-based vector in order to target cancer and other chronic diseases.
The collaboration aims to leverage Oxford BioMedica’s expertise in lentiviral vector clinical development by focusing on the design and validation of custom analytical methods, in order to facilitate the future clinical development path for Immune Design’s pre-clinical therapeutic vaccine candidate for the treatment of cancer.
John Dawson, Chief Executive Officer of Oxford BioMedica, commented: “Having successfully initiated ground-breaking clinical studies with our own gene therapy products, we pride ourselves on our translational expertise and look forward to supporting Immune Design with the transition of its therapeutic cancer vaccine into a first-in-man study.”
Carlos Paya, Chief Executive Officer of Immune Design, said: “We are very excited to be working with Oxford BioMedica on the development of our lentiviral-based vector. By capitalising on Oxford BioMedica’s expertise in lentiviral vector products, we plan to rapidly advance our novel vector to clinic for the treatment of several cancer indications.”
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sarah MacLeod, Head of Communications
Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700